The use of biomarkers in immunotherapy has some technical and biological limitations, and is complicated further by the qualitative aspect of cancer treatment, said David Fabrizio, of Foundation Medicine, Inc. A genomic-based solution could help develop more unified quantitative approaches.
The use of biomarkers in immunotherapy has some technical and biological limitations, and is complicated further by the qualitative aspect of cancer treatment, said David Fabrizio, of Foundation Medicine, Inc. A genomic-based solution could help develop more unified quantitative approaches.
Transcript (slightly modified)
Does biomarker-driven treatment remain a challenge with checkpoint inhibitors?
Yes, absolutely. I think a resounding absolutely. Our first crack at biomarkers in immunotherapy has been protein-based expression and immunohistochemistry staining, and although this does have clinical utility, there are quite a number of limitations associated with that. Some of those limitations are explained by technical aspects of that assay and biological limitations of simply looking at protein-based expression.
But I think at the end of the day, what it comes down to is that the score that you determine based on that type of assay, there’s always a human element associated with that, so there’s a qualitative aspect to it. That qualitative aspect of determining percent positivity, essentially, makes it difficult to adopt as sort of standard best practice. I think, because of that, we need more unified quantitative approaches.
We see the solution there as a genomic-based solution, and so we’ve done that through the emergence of a biomarker we call tumor mutational burden or TMB, which is really just a measure of the number of somatic mutations that exist in a patient’s cancer genome. And we’ve shown, across a number of indications actually, that TMB has quite effective clinical utility at stratifying those who actually benefit, respond, and survive longer versus those who don’t.
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More
Navigating the Mental Health Challenges of Cancer Diagnosis, Treatment, and Survivorship
March 12th 2024Stress has potential links to worse outcomes in cancer, such as decreased quality of life and greater risks of disease progression and metastasis. There is a complex mix of emotions patients with cancer experience.
Read More